Watt, GB
Alan Watt, Essex GB
Patent application number | Description | Published |
---|---|---|
20080196977 | Collapsible Access Tower - A collapsible access tower has a chassis | 08-21-2008 |
Andrew Archibald Ronald Watt, Oxfordshire GB
Patent application number | Description | Published |
---|---|---|
20150244457 | Apparatus For Data Communications, Method Of Performing Data Communications - Apparatus and methods for data communications are disclosed. In a disclosed arrangement, there is provided an apparatus for data communications, comprising: a detector for detecting electromagnetic radiation; a decoder for obtaining information from the detected electromagnetic radiation; and a concentration stage for receiving and concentrating the radiation, prior to detection of the radiation by the detector, the concentration stage comprising a wavelength converting element configured to convert radiation to longer wavelength radiation. | 08-27-2015 |
Andrew Archibald Ronald Watt, Oxford GB
Patent application number | Description | Published |
---|---|---|
20130042910 | SOLAR CELL - The present invention provides a solar cell comprising an anode ( | 02-21-2013 |
Douglas Watt, Bristol GB
Patent application number | Description | Published |
---|---|---|
20110131558 | LINK-TIME RESOURCE ALLOCATION FOR A MULTI-THREADED PROCESSOR ARCHITECTURE - A method comprising: independently compiling a plurality of modules of source code to generate a plurality of respective object modules comprising a plurality of respective parallel threads explicitly designated by a user to be executed in parallel on a target platform; in each of the object modules, inserting at least one symbol indicative of a usage of a resource of the target platform associated with the respective thread; executing a linker to perform a linking process for linking the object modules, wherein the linking process comprises assessing the symbols in conjunction with one another, and based on the assessment generating an indication relating to a usage of the resource required for execution of the threads in parallel. | 06-02-2011 |
20110131559 | COMPILING AND LINKING - A method of generating a computer program, the method comprising: independently compiling a plurality of source code modules to generate a plurality of respective object modules comprising a plurality of respective threads explicitly designated by a user to be executed in parallel; in each of the object modules, inserting at least one symbol indicative of a property of the object module's thread potentially conflicting with a corresponding property of a thread of another of said object module as a result of parallel execution of those threads; executing a linker to perform a linking process on said object modules, the linking process comprising: assessing the symbols in conjunction with one another to determine whether a conflict exists between the threads of two or more of the respective object modules; and linking the object modules to generate a computer program in which said threads are executable in parallel, wherein the linking is performed in dependence on said assessment. | 06-02-2011 |
Fiona Watt, Cambridge GB
Fiona Watt, London GB
Patent application number | Description | Published |
---|---|---|
20140023589 | FRMD4A ANTAGONISTS AND THEIR USES - An antagonist of FERM domain-containing protein 4A (FRMD4A) and/or of the Hippo pathway for use in a method of treating a cancer in a mammalian subject, wherein the cancer is selected from: squamous cell carcinoma (SCC), an epithelial cancer, an adenocarcinoma and a carcinoma is disclosed, as well as related methods of treatment of cancer, methods of screening and generating such antagonists, including anti-FRMD4A antibodies. | 01-23-2014 |
Gillian Sairfull Watt, Luton GB
Patent application number | Description | Published |
---|---|---|
20140080134 | LIPOCALIN 2 AS A BIOMARKER FOR IL-17 INHIBITOR THERAPY EFFICACY - The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy. | 03-20-2014 |
Greg Watt, Bristol GB
Patent application number | Description | Published |
---|---|---|
20150361132 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES - Provided are compounds of Formula I: | 12-17-2015 |
Gregory M. Watt, Bristol GB
Patent application number | Description | Published |
---|---|---|
20130022573 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES - Provided are compounds of Formula I: | 01-24-2013 |
20140023616 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES - Provided are compounds of Formula I: | 01-23-2014 |
Kieran James Watt, Fulwood GB
Patent application number | Description | Published |
---|---|---|
20130283816 | TURBOPROP-POWERED AIRCRAFT - A turboprop-powered medium altitude long endurance aircraft, having a gas turbine engine; a heat scavenging device to scavenge heat from the gas turbine engine; and a heating device to use the scavenged heat to provide heating to the aircraft. The heat scavenging device may be placed on an engine casing and/or on or in an engine exhaust duct. The heating device may include a circulation path routed directly to a location in the aircraft where heating is to be performed, for example a leading edge of an engine support pylon or a leading edge of an engine-carrying wing. The heating device can include a heat exchanger. | 10-31-2013 |
Kieran Jamess Watt, Fulwood GB
Patent application number | Description | Published |
---|---|---|
20130292085 | TURBOPROP-POWERED AIRCRAFT - A method and apparatus are disclosed for a turboprop-powered medium altitude long endurance (MALE) aircraft, having: a heat exchanger with a heat-storage material, for example a heat-storage wax; and an air recirculation path. The heat exchanger can be arranged to cool air recirculating around the air recirculation path which is arranged to provide cooling to the MALE aircraft, for example to an equipment bay. The heat-storage material may be cooled by ground-based cooling apparatus when the aircraft is on the ground and/or by ram air when the aircraft is in flight. The heat-storage material may have a melting point selected so as to be rendered solid during ground-based cooling and/or ram air cooling, and/or selected so as to undergo melting whilst cooling the air recirculating around the air recirculation path. | 11-07-2013 |
Lyndsay Claire Watt, London GB
Patent application number | Description | Published |
---|---|---|
20150334069 | Notifications - A notification of a received communication relating to a communication chain is presented. An input is received in response to that notification. Until a predetermined event occurs, the presentation of at least one type of notification of further received communications relating to that communication chain is suspended in dependence on said input. | 11-19-2015 |
Paul Watt, West Yorkshire GB
Patent application number | Description | Published |
---|---|---|
20080269451 | Antimicrobial Polymers - The present invention is concerned with providing antimicrobial compounds and processes for the production thereof. More particularly, the present invention provides antimicrobial polymeric materials comprising a polymer linked to a positively charged moiety via a carboxyl group. The present invention also provides processes for the production of such antimicrobial compounds and uses therefor. | 10-30-2008 |
Paul William Watt, Steeton GB
Patent application number | Description | Published |
---|---|---|
20090215917 | ANTIMICROBIAL POLYURETHANE FOAMS - This invention relates to antimicrobial polyurethane foams and to a method of making antimicrobial polyurethane foams. The invention also relates to the use of such foams in the production of medical devices and pharmaceutical compositions. | 08-27-2009 |
Rosalynne Sophie Watt, Bristol GB
Patent application number | Description | Published |
---|---|---|
20130061918 | PROCESS FOR THE FORMATION OF A SILVER BACK ELECTRODE OF A PASSIVATED EMITTER AND REAR CONTACT SILICON SOLAR CELL - A process for the formation of an electrically conductive silver back electrode of a PERC silicon solar cell comprising the steps: | 03-14-2013 |
20130074916 | PROCESS FOR THE PRODUCTION OF A MWT SILICON SOLAR CELL - A process for the production of a MWT silicon solar cell, wherein a conductive metal paste with no or only poor fire-through capability is applied, dried and fired to form a continuous metallization comprising a top set of conductive metal collector lines and a metallization of the inside of the holes of a p-type MWT silicon solar cell wafer, wherein the top set of conductive metal collector lines superimposes a bottom set of conductive metal collector lines on the front-side of the p-type MWT silicon solar cell wafer, said bottom set of conductive metal collector lines having no contact with the inside of the holes. | 03-28-2013 |
20130074917 | PROCESS FOR THE PRODUCTION OF A MWT SILICON SOLAR CELL - A process for the production of a MWT silicon solar cell, wherein a conductive metal paste with no or only poor fire-through capability is applied, dried and fired to form a continuous metallization comprising a top set of conductive metal collector lines and a metallization of the inside of the holes of an n-type MWT silicon solar cell wafer, wherein the top set of conductive metal collector lines superimposes a bottom set of conductive metal collector lines on the front-side of the n-type MWT silicon solar cell wafer, said bottom set of conductive metal collector lines having no contact with the inside of the holes. | 03-28-2013 |
20130192670 | ALUMINUM PASTE AND USE THEREOF IN THE PRODUCTION OF PASSIVATED EMITTER AND REAR CONTACT SILICON SOLAR CELLS - An aluminum paste having no or only poor fire-through capability and comprising particulate aluminum, an organic vehicle and at least one glass frit selected from the group consisting of lead-free glass frits containing 0.5 to 15 wt. % SiO | 08-01-2013 |
20130192671 | CONDUCTIVE METAL PASTE AND USE THEREOF - A conductive metal paste having no or only poor fire-through capability and including (a) particulate silver, (b) at least one lead-free glass frit including 0.5 to 15 wt. % SiO | 08-01-2013 |
Simon Watt, Burwell Cambs GB
Patent application number | Description | Published |
---|---|---|
20100312810 | SECURE IDENTIFICATION OF MUSIC FILES - Digital content files may include media content, metadata uniquely identifying a transaction in which the content file was obtained, and a digital signature of at least a portion of the metadata. The metadata may include a distributor ID, a date and time of the transaction, an asset ID, a secure hash of the media content, a nonce, and one of a user ID, uniquely identifying a user who obtained the content file in the transaction, and a transaction ID uniquely identifying the transaction. | 12-09-2010 |
Simon Charles Watt, Cambridge GB
Patent application number | Description | Published |
---|---|---|
20090235092 | Transferring data values via a data bus or storing data values using a selectable representation - Data values being stored and transferred within a data processing system | 09-17-2009 |
20090259846 | Exception types within a secure processing system - An apparatus for processing data includes a processor operable in a plurality modes including at least one secure mode being a mode in a secure domain and at least one non-secure mode being a mode in a non-secure domain. When the processor is executing a program in a secure mode the program has access to secure data which is not accessible when the processor is operating in a non-secure mode. The processor is responsive to one or more exception conditions for triggering exception processing using an exception handler. The processor is operable to select the exception handler from among a plurality of possible exception handlers in dependence upon whether the processor is operating in the secure domain or the non-secure domain. | 10-15-2009 |
20090320048 | TASK FOLLOWING BETWEEN MULTIPLE OPERATING SYSTEMS - A processor may utilise two operating systems (Non-Secure, Secure) between which calls may be made. In order that a second operating system can track task switches made by a first operating system, each time a call is made to the second operating system, this call includes an identifier to enable discrimination between the task which was executing on the first operating system when that call was made. The identifier can be a call identifier and/or a target thread identifier and may include further parameters. | 12-24-2009 |
Stephen Watt, Dundee GB
Patent application number | Description | Published |
---|---|---|
20130336987 | Identification of Therapeutic Targets in Cutaneous SCC - The present invention discloses a series of genes and/or proteins associated with cutaneous squamous cell carcinoma (cSCC) and provides polynucleotides and/or polypeptides for use in the treatment and/or prevention of cSCC. The invention further relates to methods of diagnosing cSCC and provides oligonucleotides/polypeptide probes and primers. | 12-19-2013 |
20150352191 | TREATMENT OF SKIN DISORDERS - The present invention is based upon the finding that certain conditions, diseases and/or disorders affecting the skin, are associated with reduced expression of an enzyme exhibiting oxidoreductase activity. Accordingly, the invention provides oxidoreductase enzymes and/or genes encoding the same for use in treating or preventing disorders of the skin and method for generating Type VII collagen suitable for use in treating disorders of the skin. | 12-10-2015 |
Stephen Watt, Cambridgeshire GB
Stephen Watt, Riccarton GB
Patent application number | Description | Published |
---|---|---|
20100160426 | CRYSTALLINE GENISTEIN SODIUM SALT DIHYDRATE - The disclosure relates to a new crystalline form of genistein. The disclosed crystalline form is crystalline genistein sodium salt dihydrate. The disclosure also relates to the novel genistein salt composition represented by this crystalline form. Therapeutic compositions containing crystalline genistein sodium salt and a pharmaceutically acceptable carrier are described. The disclosure also relates to therapeutic methods comprising the step of administering to a patient in need thereof a therapeutically effective amount of a therapeutic composition containing the crystalline form of the disclosure or crystalline genistein sodium salt dihydrate. | 06-24-2010 |
20120035253 | CRYSTALLINE FORMS OF GENISTEIN - The disclosure relates to new crystalline forms of genistein. The disclosed crystalline forms include crystalline genistein sodium salt dihydrate; crystalline genistein potassium salt dihydrate; crystalline genistein calcium salt; crystalline genistein magnesium salt; crystalline genistein L-lysine salt; crystalline genistein N-methylglucamine salt; crystalline genistein N-ethylglucamine salt; crystalline genistein diethylamine salt; and crystalline genistein monohydrate. The disclosure also relates to the novel genistein salts represented by these crystalline forms. Therapeutic compositions containing at least one of these crystalline forms of genistein and/or a genistein salt and a pharmaceutically acceptable carrier are described. The disclosure also relates to methods of treating cancer comprising the step of administering to a patient in need thereof a therapeutically effective amount of a therapeutic composition containing the compounds of the disclosure, of a crystalline form of genistein, or of a genistein salt. | 02-09-2012 |
20150290166 | CRYSTALLINE FORMS OF GENISTEIN - The disclosure relates to new crystalline forms of genistein. The disclosed crystalline forms include crystalline genistein sodium salt dihydrate; crystalline genistein potassium salt dihydrate; crystalline genistein calcium salt; crystalline genistein magnesium salt; crystalline genistein L-lysine salt; crystalline genistein N-methylglucamine salt; crystalline genistein N-ethylglucamine salt; crystalline genistein diethylamine salt; and crystalline genistein monohydrate. The disclosure also relates to the novel genistein salts represented by these crystalline forms. Therapeutic compositions containing at least one of these crystalline forms of genistein and/or a genistein salt and a pharmaceutically acceptable carrier are described. The disclosure also relates to methods of treating cancer comprising the step of administering to a patient in need thereof a therapeutically effective amount of a therapeutic composition containing the compounds of the disclosure, of a crystalline form of genistein, or of a genistein salt. | 10-15-2015 |
Stephen Watt, East Lothian GB
Patent application number | Description | Published |
---|---|---|
20160081946 | 4:3 NALTREXONE: 5-METHYL-2-FURALDEHYDE COCRYSTAL - A 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal and its use as an opioid antagonist are disclosed. The invention also relates to a drug-in-adhesive transdermal patch containing the analgesic fentanyl, a mu opioid agonist, or an analog thereof and a 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal, as an opioid antagonist. A transdermal patch of the invention is tamper-resistant and an abuse deterrent which protects against drug misuse or abuse. The invention also provides a method of treating pain, such as acute, chronic, or intermittent pain, by applying a drug-in-adhesive transdermal patch according to the invention to the skin of a patient in need thereof. Also disclosed is an improved transdermal patch for administering fentanyl or an analog thereof, or for administering a mu opioid agonist, the improvement wherein the transdermal patch contains a 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal in an abuse limiting amount. The improved transdermal patch may be a drug-in-adhesive transdermal patch or a reservoir transdermal patch. | 03-24-2016 |
Stephen W. Watt, East Lothian GB
Patent application number | Description | Published |
---|---|---|
20110245234 | CRYSTALLINE FORMS OF SODIUM 4--2-METHOXYBENZOATE - The present invention is directed to a compound of formula (I): | 10-06-2011 |
20140357622 | CRYSTALLINE FORMS OF SODIUM 4--2-METHOXYBENZOATE - The present invention is directed to a compound of formula (I): | 12-04-2014 |
Stephen William Watt, Tranent GB
Patent application number | Description | Published |
---|---|---|
20100280119 | L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF - Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate. | 11-04-2010 |
20120208885 | L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF - Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate. | 08-16-2012 |
20130211135 | METHODS OF MAKING L-ORNITHINE PHENYL ACETATE - Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, inter-mixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt in situ. The present application also relates to various compositions obtained from these processes, including crystalline forms. | 08-15-2013 |
20130296429 | L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF - Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate. | 11-07-2013 |
20140288327 | L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF - Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate. | 09-25-2014 |
20150133684 | METHODS OF MAKING L-ORNITHINE PHENYL ACETATE - Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, intermixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt in situ. The present application also relates to various compositions obtained from these processes, including crystalline forms. | 05-14-2015 |
20150251990 | L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF - Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate. | 09-10-2015 |
Stephen William Watt, Chatteris GB
Patent application number | Description | Published |
---|---|---|
20090042847 | 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN POLYMORPHS AND FORMULATIONS - Polymorphs and pharmaceutical formulations of 17-allylamino-17-demethoxy-geldanamycin (17-AAG). | 02-12-2009 |
Suzanne Watt, Headington GB
Patent application number | Description | Published |
---|---|---|
20130108594 | METHOD FOR EVALUATING ANGIOGENIC POTENTIAL | 05-02-2013 |
Thomas Watt, St Ives GB
Patent application number | Description | Published |
---|---|---|
20150219531 | EXTRACTION APPARATUS AND METHOD - Disclosed is apparatus for distributing a solid, gel, powder or viscous test substance in an extraction fluid, the apparatus comprising a flow cell for holding the test substance and having an inlet and an outlet; an extraction chamber located between said inlet and outlet comprising a convergent nozzle; and a recirculating pump for driving extraction fluid: (i) into the flow cell via the inlet; (ii) through the extraction chamber; and (iii) back to the flow cell via the outlet, whereby a pressure differential is established across the extraction chamber such that the velocity of the extraction fluid is greater at the outlet than at the inlet; characterized in that the apparatus further comprises a tortuous path flow control valve (TPV) located at the outlet and configured to permit flow of extraction fluid and extracted test substance but to prevent or retard passage of said test substance through the outlet. | 08-06-2015 |